Alzheimer's disease (AD) is a progressive neurodegenerative disease with limited prevention and treatment options.
Objective
We aimed to identify proteins with genetically regulated plasma levels associated with AD and its related phenotypes.
Methods
We conducted a proteome-wide association study (PWAS) using Olink-based plasma proteomes (N = 45,540) from the UK Biobank Pharma Proteomics Project (UKB-PPP) and a large-scale genome-wide association study for AD (N case = 85,934, N control = 401,577). To validate and expand these findings, we conducted longitudinal analyses of AD and mild cognitive disorder (MCD) over a 13.7-year follow-up, along with genetic-based PWAS analyses and cross-sectional studies on hippocampal volume. Protein-protein interaction networks were constructed to explore mechanistic association.
Results
We identified 30 AD-associated plasma proteins by PWAS, including 17 previously reported and 13 novel candidates (including FES, LRP11, and HDGF). Longitudinal cohort studies supported the role of PILRB and FES in AD and/or MCD. Additionally, the genetically determined higher levels of LRP11 were found to be associated with an increased hippocampal volume, including its subdivisions, along with a reduced risk of AD. In contrast, higher plasma levels of HDGF were linked to a decreased hippocampal volume, accompanied by an increased risk of AD. Protein-protein interaction analysis linked PILRA, PILRB, FES, and LRP11 to several pathological proteins associated with AD, including BIN1, ABCA7, and SORL1.
Conclusions
This study identified 13 novel candidates, with potential roles in hippocampal volume and AD risk, providing insights into disease mechanisms.
NicholsESteinmetzJDVollsetSE, et al.Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019. Lancet Public Health2022; 7: e105–e125.
2.
ScheltensPDe StrooperBKivipeltoM, et al.Alzheimer’s disease. Lancet2021; 397: 1577–1590.
3.
JaffeS. US FDA defends approval of Alzheimer’s disease drug. Lancet2021; 398: 12.
4.
WangZ-BWangZ-TSunY, et al.The future of stem cell therapies of Alzheimer’s disease. Ageing Res Rev2022; 80: 101655.
5.
PanyardDJMcKetneyJDemingYK, et al.Large-scale proteome and metabolome analysis of CSF implicates altered glucose and carbon metabolism and succinylcarnitine in Alzheimer’s disease. Alzheimers Dement2023; 19: 5447–5470.
6.
ChatterjeePPedriniSDoeckeJD, et al.Plasma Aβ42/40 ratio, p-tau181, GFAP, and NfL across the Alzheimer’s disease continuum: a cross-sectional and longitudinal study in the AIBL cohort. Alzheimers Dement2023; 19: 1117–1134.
7.
BaiBVanderwallDLiY, et al.Proteomic landscape of Alzheimer’s disease: novel insights into pathogenesis and biomarker discovery. Mol Neurodegener2021; 16: 55.
8.
SuthaharNWangDAboumsallemJP, et al.Association of initial and longitudinal changes in C-reactive protein with the risk of cardiovascular disease, cancer, and mortality. Mayo Clin Proc2023; 98: 549–558.
9.
HagströmEJamesSKBertilssonM, et al.Growth differentiation factor-15 level predicts major bleeding and cardiovascular events in patients with acute coronary syndromes: results from the PLATO study. Eur Heart J2016; 37: 1325–1333.
10.
OuY-NYangY-XDengY-T, et al.Identification of novel drug targets for Alzheimer’s disease by integrating genetics and proteomes from brain and blood. Mol Psychiatry2021; 26: 6065–6073.
11.
WingoAPLiuYGerasimovES, et al.Integrating human brain proteomes with genome-wide association data implicates new proteins in Alzheimer’s disease pathogenesis. Nat Genet2021; 53: 143–146.
12.
ZhouDJiangYZhongX, et al.A unified framework for joint-tissue transcriptome-wide association and Mendelian randomization analysis. Nat Genet2020; 52: 1239–1246.
13.
WainbergMSinnott-ArmstrongNMancusoN, et al.Opportunities and challenges for transcriptome-wide association studies. Nat Genet2019; 51: 592–599.
14.
SudlowCGallacherJAllenN, et al.UK Biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. PLoS Med2015; 12: e1001779.
15.
AlmarriMABergströmAPrado-MartinezJ, et al.Population structure, stratification, and introgression of human structural variation. Cell2020; 182: 189–199.e15.
16.
SunBBChiouJTraylorM, et al.Plasma proteomic associations with genetics and health in the UK Biobank. Nature2023; 622: 329–338.
17.
Carrasco-ZaniniJPietznerMDavitteJ, et al.Proteomic prediction of common and rare diseases. Nat Med2024; 30: 2489–2498.
18.
HeymansMWTwiskJWR. Handling missing data in clinical research. J Clin Epidemiol2022; 151: 185–188.
19.
Carrasco-ZaniniJPietznerMDavitteJ, et al.Proteomic signatures improve risk prediction for common and rare diseases. Nat Med2024; 30: 2489–2498.
20.
BellenguezCKüçükaliFJansenIE, et al.New insights into the genetic etiology of Alzheimer’s disease and related dementias. Nat Genet2022; 54: 412–436.
21.
SmithSMDouaudGChenW, et al.An expanded set of genome-wide association studies of brain imaging phenotypes in UK Biobank. Nat Neurosci2021; 24: 737–745.
22.
Alfaro-AlmagroFJenkinsonMBangerterNK, et al.Image processing and quality control for the first 10,000 brain imaging datasets from UK Biobank. Neuroimage2018; 166: 400–424.
23.
GamazonERWheelerHEShahKP, et al.A gene-based association method for mapping traits using reference transcriptome data. Nat Genet2015; 47: 1091–1098.
24.
ZhuZZhangFHuH, et al.Integration of summary data from GWAS and eQTL studies predicts complex trait gene targets. Nat Genet2016; 48: 481–487.
25.
LongJMHoltzmanDM. Alzheimer disease: an update on pathobiology and treatment strategies. Cell2019; 179: 312–339.
26.
MountjoyESchmidtEMCarmonaM, et al.An open approach to systematically prioritize causal variants and genes at all published human GWAS trait-associated loci. Nat Genet2021; 53: 1527–1533.
27.
KingEADavisJWDegnerJF. Are drug targets with genetic support twice as likely to be approved? Revised estimates of the impact of genetic support for drug mechanisms on the probability of drug approval. PLoS Genet2019; 15: e1008489.
28.
KunkleBWGrenier-BoleyBSimsR, et al.Genetic meta-analysis of diagnosed Alzheimer’s disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing. Nat Genet2019; 51: 414–430.
29.
Amlie-WolfATangMMlynarskiEE, et al.INFERNO: inferring the molecular mechanisms of noncoding genetic variants. Nucleic Acids Res2018; 46: 8740–8753.
30.
NovikovaGKapoorMTcwJ, et al.Integration of Alzheimer’s disease genetics and myeloid genomics identifies disease risk regulatory elements and genes. Nat Commun2021; 12: 1610.
31.
QiCLövestamSMurzinAG, et al.Tau filaments with the Alzheimer fold in human MAPT mutants V337M and R406W. Nat Struct Mol Biol2025; 32: 1297–1304.
32.
SzklarczykDKirschRKoutrouliM, et al.The STRING database in 2023: protein–protein association networks and functional enrichment analyses for any sequenced genome of interest. Nucleic Acids Res2023; 51: D638–D646.
GiambartolomeiCVukcevicDSchadtEE, et al.Bayesian Test for colocalisation between pairs of genetic association studies using summary statistics. PLoS Genet2014; 10: e1004383.
35.
NalivaevaNNTurnerAJ. AChe and the amyloid precursor protein (APP) – Cross-talk in Alzheimer’s disease. Chem Biol Interact2016; 259: 301–306.
36.
PanYLiHWangY, et al.Causal effect of Lp(a) [lipoprotein(a)] level on ischemic stroke and Alzheimer disease. Stroke2019; 50: 3532–3539.
37.
ZhuX-CYuJ-TJiangT, et al.CR1 In Alzheimer’s disease. Mol Neurobiol2015; 51: 753–765.
38.
ZuroffLRTorbatiTHartNJ, et al.Effects of IL-34 on macrophage immunological profile in response to Alzheimer’s-related Aβ42 assemblies. Front Immunol2020; 11: 1449.
39.
RhinnHTattonNMcCaugheyS, et al.Progranulin as a therapeutic target in neurodegenerative diseases. Trends Pharmacol Sci2022; 43: 641–652.
40.
WesternDTimsinaJWangL, et al.Proteogenomic analysis of human cerebrospinal fluid identifies neurologically relevant regulation and implicates causal proteins for Alzheimer’s disease. Nat Genet2024; 56: 2672–2684.
41.
HelgadottirHTLundinPWallén ArztE, et al.Somatic mutation that affects transcription factor binding upstream of CD55 in the temporal cortex of a late-onset Alzheimer disease patient. Hum Mol Genet2019; 28: 2675–2685.
42.
WangS-YFuX-XDuanR, et al.The Alzheimer’s disease-associated gene TREML2 modulates inflammation by regulating microglia polarization and NLRP3 inflammasome activation. Neural Regen Res2023; 18: 434.
43.
TaoQ-QChenY-CWuZ-Y. The role of CD2AP in the pathogenesis of Alzheimer’s disease. Aging Dis2019; 10: 901–907.
44.
CarmonaSZahsKWuE, et al.The role of TREM2 in Alzheimer’s disease and other neurodegenerative disorders. Lancet Neurol2018; 17: 721–730.
45.
ZhanHCammannDCummingsJL, et al.Biomarker identification for Alzheimer’s disease through integration of comprehensive Mendelian randomization and proteomics data. J Transl Med2025; 23: 278.
46.
KimuraKSubramanianAYinZ, et al.Immune checkpoint TIM-3 regulates microglia and Alzheimer’s disease. Nature2025; 641: 718–731.
47.
VeteleanuAStevenson-HoareJKeatS, et al.Alzheimer’s disease-associated complement gene variants influence plasma complement protein levels. J Neuroinflammation2023; 20: 169.
48.
ZhaiWSunLFangW, et al.Cross-ancestry information transfer framework improves protein abundance prediction and protein-trait association identification. 2025; 2025.08.13.670235.
49.
JiangSLiHZhangL, et al.Generic Diagramming Platform (GDP): a comprehensive database of high-quality biomedical graphics. Nucleic Acids Res2025; 53: D1670–D1676.
50.
DourlenPKilincDLandrieuI, et al.BIN1 and Alzheimer’s disease: the tau connection. Trends Neurosci2025; 48: 349–361.
51.
ReusLMJansenIETijmsBM, et al.Connecting dementia risk loci to the CSF proteome identifies pathophysiological leads for dementia. Brain2024; 147: 3522–3533.
52.
LuQLuGQiJ, et al.PILRα and PILRβ have a siglec fold and provide the basis of binding to sialic acid. Proc Natl Acad Sci U S A2014; 111: 8221–8226.
53.
SmithAMDaveyKTsartsalisS, et al.Diverse human astrocyte and microglial transcriptional responses to Alzheimer’s pathology. Acta Neuropathol2022; 143: 75–91.
54.
SchwartzentruberJCooperSLiuJZ, et al.Genome-wide meta-analysis, fine-mapping and integrative prioritization implicate new Alzheimer’s disease risk genes. Nat Genet2021; 53: 392–402.
55.
LiYLawsSMMilesLA, et al.Genomics of Alzheimer’s disease implicates the innate and adaptive immune systems. Cell Mol Life Sci2021; 78: 7397–7426.
56.
RathoreNRamaniSRPantuaH, et al.Paired immunoglobulin-like type 2 receptor alpha G78R variant alters ligand binding and confers protection to Alzheimer’s disease. PLoS Genet2018; 14: e1007427.
57.
MonroeKWeerakkodyTSabelströmH, et al.PILRA regulates microglial neuroinflammation and lipid metabolism as a candidate therapeutic target for Alzheimer’s disease. Res Sq2024. DOI:10.21203/rs.3.rs-3954863/v1. [Preprint]. Posted 15 February 2024.
58.
RyanKJWhiteCCPatelK, et al.A human microglia-like cellular model for assessing the effects of neurodegenerative disease gene variants. Sci Transl Med2017; 9: 3aai7635.
59.
ZhaoL. CD33 In Alzheimer’s disease – biology, pathogenesis, and therapeutics: a mini-review. Gerontology2018; 65: 323–331.
60.
RanganathanSNoyesNCMiglioriniM, et al.LRAD3, A novel low-density lipoprotein receptor family member that modulates amyloid precursor protein trafficking. J Neurosci2011; 31: 10836–10846.
61.
GuoJChenSHuangC, et al.MANSC: a seven-cysteine-containing domain present in animal membrane and extracellular proteins. Trends Biochem Sci2004; 29: 172–174.
62.
MarksNBergMJ. Neurosecretases provide strategies to treat sporadic and familial Alzheimer disorders. Neurochem Int2008; 52: 184–215.
63.
KarchCMGoateAM. Alzheimer’s disease risk genes and mechanisms of disease pathogenesis. Biol Psychiatry2015; 77: 43–51.
64.
KimBHKimYJKimM-H, et al.Identification of FES as a novel radiosensitizing target in human cancers. Clin Cancer Res2020; 26: 265–273.
65.
LaurentCESmithgallTE. The c-Fes tyrosine kinase cooperates with the breakpoint cluster region protein (Bcr) to induce neurite extension in a Rac- and Cdc42-dependent manner. Exp Cell Res2004; 299: 188–198.
66.
RosenbergerAFNHilhorstRCoartE, et al.Protein kinase activity decreases with higher Braak stages of Alzheimer’s disease pathology. J Alzheimers Dis2016; 49: 927–943.
67.
SudwartsARameshaSGaoT, et al.BIN1 Is a key regulator of proinflammatory and neurodegeneration-related activation in microglia. Mol Neurodegener2022; 17: 33.
68.
PonnusamyMWangSYukselM, et al.Loss of forebrain BIN1 attenuates hippocampal pathology and neuroinflammation in a tauopathy model. Brain2023; 146: 1561–1579.
ZhouZYamamotoYSugaiF, et al.Hepatoma-derived growth factor is a neurotrophic factor harbored in the nucleus. J Biol Chem2004; 279: 27320–27326.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
